Proprietary pipeline of next generation immunology and immuno-oncology drugs.

numab graphic numab graphic numab graphic numab graphic

Highlights of tech platform & competitive edge

Using a novel, rational process, our proprietary discovery and engineering technology yields multispecific antibody-based therapeutics with tailored pharmacokinetic properties that improve on first generation antibody therapies in terms of potency, stability, effect duration and safety. Alongside our own in-house pipeline programs we have a number of strong discovery and development partnerships with pharma and biotech.

Latest News
September 14, 2017

Intarcia and Numab Reach Key Milestone, Numab to Initiate Financing Round of CHF 30 Million

Intarcia Therapeutics, Inc., and Numab Therapeutics AG today…

Intarcia Therapeutics, Inc., and Numab Therapeutics AG today announced the achievement of a key milestone in their on-going development partnership – the selection of a multi-specific antibody construct targeting autoimmune and inflammatory diseases. This delivery marks the first major milestone in the strategic relationship, established in the spring of 2015, and triggers a payment to Numab that will bring the total payments for this project to CHF 11.5 million to date.  
June 13, 2017

Numab and Kaken Pharmaceutical Co., Ltd. Enter into a Collaboration and Option Agreement

Numab Therapeutics AG (“Numab”) today announced a…

Numab Therapeutics AG ("Numab") today announced a collaboration and option agreement with Kaken Pharmaceutical Co., Ltd. ("Kaken") for the identification of a multispecific antibody candidate for development in inflammatory disease. Under the agreement, Kaken will obtain an option to conclude a license and co-development agreement after identification of lead candidate generated by Numab using its unique multispecific antibody technology platform. Kaken is to fully fund the research program.
March 28, 2017

Numab and Ono Pharmaceutical Co., Ltd. Enter into a Research and Option Agreement

Numab Therapeutics AG (“Numab”) today announced a research and…

Numab Therapeutics AG (“Numab”) today announced a research and option agreement with Ono Pharmaceutical Co., Ltd. (“Ono”) for the identification of a multi-specific antibody candidate for development in immunooncology.
More News